TNYA (Tenaya Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by TNYA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-17 | Whittemore Tingley | Chief Medical Officer | Sell | — | — |
| 2026-08-17 | Faraz Ali | Chief Executive Officer | Sell | — | — |
| 2026-07-14 | Eric J Hyllengren | Chief Financial Officer | A | — | — |
| 2026-05-29 | Deepak Srivastava | Director | A | — | — |
| 2026-05-29 | Catherine Stehman-Breen | Director | A | — | — |
| 2026-05-29 | Amy L. Burroughs | Director | A | — | — |
| 2026-05-29 | Karah Herdman Parschauer | Director | A | — | — |
| 2026-05-29 | June Lee | Director | A | — | — |
| 2026-05-29 | Jeffrey T. Walsh | Director | A | — | — |
| 2026-05-29 | R Sanders Williams | Director | A | — | — |
| 2026-05-19 | Tomohiro Higa | SVP, Finance | Sell | — | — |
| 2026-05-19 | Whittemore Tingley | Chief Medical Officer | Sell | — | — |
| 2026-05-19 | Faraz Ali | Chief Executive Officer | Sell | — | — |
| 2026-02-26 | COLUMN GROUP III GP, LP | 10%+ Owner | Sell | — | — |
| 2026-02-24 | Column Group Opportunity III GP, LP | 10%+ Owner | Sell | — | — |
| 2026-02-17 | Tomohiro Higa | SVP, Finance | Sell | — | — |
| 2026-02-17 | Faraz Ali | Chief Executive Officer | Sell | — | — |
| 2026-02-17 | Whittemore Tingley | Chief Medical Officer | Sell | — | — |
| 2026-02-12 | TCG Opportunity III GP, LLC | 10%+ Owner | Sell | — | — |
| 2026-02-05 | Faraz Ali | Chief Executive Officer | A | — | — |
| 2026-02-05 | Whittemore Tingley | Chief Medical Officer | A | — | — |
| 2026-02-05 | Tomohiro Higa | SVP, Finance | A | — | — |
| 2025-11-17 | Faraz Ali | Chief Executive Officer | Sell | — | — |
| 2025-11-17 | Whittemore Tingley | Chief Medical Officer | Sell | — | — |
| 2025-11-17 | Tomohiro Higa | SVP, Finance | Sell | — | — |
| 2025-08-18 | Whittemore Tingley | Chief Medical Officer | Sell | — | — |
| 2025-08-18 | Tomohiro Higa | SVP, Finance | Sell | — | — |
| 2025-08-18 | Faraz Ali | Chief Executive Officer | Sell | — | — |
| 2025-05-30 | R Sanders Williams | Director | A | — | — |
| 2025-05-30 | Amy L. Burroughs | Director | A | — | — |
| 2025-05-30 | Deepak Srivastava | Director | A | — | — |
| 2025-05-30 | Catherine Stehman-Breen | Director | A | — | — |
| 2025-05-30 | DAVID V GOEDDEL | Director | A | — | — |
| 2025-05-30 | Karah Herdman Parschauer | Director | A | — | — |
| 2025-05-30 | Jeffrey T. Walsh | Director | A | — | — |
| 2025-05-30 | June Lee | Director | A | — | — |
| 2025-05-16 | Faraz Ali | Chief Executive Officer | Sell | — | — |
| 2025-05-16 | Tomohiro Higa | SVP, Finance | Sell | — | — |
| 2025-05-16 | Whittemore Tingley | Chief Medical Officer | Sell | — | — |
| 2025-03-10 | Tomohiro Higa | SVP, Finance | Sell | — | — |
| 2025-03-10 | Faraz Ali | Chief Executive Officer | Sell | — | — |
| 2025-03-10 | Whittemore Tingley | Chief Medical Officer | Sell | — | — |
| 2025-03-07 | DAVID V GOEDDEL | Director | Buy | — | — |
| 2025-03-07 | COLUMN GROUP III GP, LP | 10%+ Owner | Buy | — | — |
| 2025-02-07 | Faraz Ali | Chief Executive Officer | A | — | — |
| 2025-01-28 | Whittemore Tingley | Chief Medical Officer | A | — | — |
| 2024-11-18 | Chihiro Saito | SVP, Accounting and Fin. Ops. | Sell | — | — |
| 2024-10-21 | DAVID V GOEDDEL | Director | A | — | — |
| 2024-10-21 | R Sanders Williams | Director | A | — | — |
| 2024-10-21 | Deepak Srivastava | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 6,078,860 | — |
| — | Director | 4,985,570 | — |
| — | 10%+ Owner | 4,414,720 | — |
| — | 10%+ Owner | 4,414,720 | — |
| — | 10%+ Owner | 4,253,298 | — |
| — | Director | 3,224,849 | — |
| — | 10%+ Owner | 2,374,048 | — |
| — | Director | 564,101 | — |
| — | Chief Executive Officer | 430,208 | — |
| — | Chief Scientific Officer | 245,346 | — |
| — | Chief Medical Officer | 219,860 | — |
| — | SVP, Finance | 118,267 | — |
| — | Chief Fin. and Bus. Officer | 95,755 | — |
| — | SVP, Accounting and Fin. Ops. | 60,983 | — |
| — | Director | 25,000 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TNYA quote page; the site-wide leaderboard is on the insider transactions hub.